Small molecule peptide
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
527
NCT03780972
A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 21, 2019
Completion: Aug 24, 2022
NCT04744662
ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Start: Jul 8, 2021
Completion: Feb 29, 2024
NCT05160805
A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
Start: May 2, 2022
Completion: Apr 9, 2024
NCT05730218
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
Phase: Phase 2
Start: Apr 4, 2023
Completion: Feb 21, 2024
NCT06659445
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Start: Mar 31, 2025
Completion: Nov 30, 2027
Loading map...